Login Register Cart 0
Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Synchronized Glioma Insights: Trends, Blood Group Correlations, Staging Dynamics, and the Vanguard of Liquid Biopsy Advancements

In Press, (this is not the final "Version of Record"). Available online 02 July, 2024
Author(s): Ryan Adnan Sheikh, Salma Naqvi*, Ayman Mohammed Al-Sulami, Mohammed Bayamin, Abdullaha Samsahan, Mirza Rafi Baig, Fahad A. Al-Abbasi, Naif A.R. Almalki, Turky Omar Asar and Firoz Anwar*
Published on: 02 July, 2024

DOI: 10.2174/0118715273306577240612053957

Price: $95

Abstract

Background: Gliomas are the most frequent, heterogeneous group of tumors arising from glial cells, characterized by difficult monitoring, poor prognosis, and fatality. Tissue biopsy is an established procedure for tumor cell sampling that aids diagnosis, tumor grading, and prediction of prognosis.

Materials and Methods: We studied and compared the levels of liquid biopsy markers in patients with different grades of glioma. Also, we tried to prove the potential association between glioma and specific blood group antigens.

Results: 78 patients were found, among whom the maximum percentage with glioblastoma had blood group O+ (53.8%). The second highest frequency had blood group A+ (20.4%), followed by B+ (9.0%) and A- (5.1%), and the least with O-. Liquid biopsy biomarkers included Alanine Aminotransferase (ALT), Lactate Dehydrogenase (LDH), lymphocytes, Urea, Alkaline phosphatase (AST), Neutrophils, and C-Reactive Protein (CRP). The levels of all the components increased significantly with the severity of the glioma, with maximum levels seen in glioblastoma (grade IV), followed by grade III and grade II, respectively.

Conclusion: Gliomas have significant clinical challenges due to their progression with heterogeneous nature and aggressive behavior. A liquid biopsy is a non-invasive approach that aids in setting up the status of the patient and figuring out the tumor grade; therefore, it may show diagnostic and prognostic utility. Additionally, our study provides evidence to prove the role of ABO blood group antigens in the development of glioma. However, future clinical research on liquid biopsy will improve the sensitivity and specificity of these tests and confirm their clinical usefulness to guide treatment approaches.

[1]
Nafe R, Hattingen E. The spectrum of molecular pathways in gliomas : An up-to-date review. Biomedicines 2023; 11(8): 2281.
[http://dx.doi.org/10.3390/biomedicines11082281] [PMID: 37626776]
[2]
Wang LM. Human brain and spinal cord tumors: From bench to bedside. In: The Path to Bedside Management. Springer International Publishing 2023; 2: pp. 1-30.
[3]
Pagano C, Navarra G, Coppola L, et al. Impacts of environmental pollution on brain tumorigenesis. Int J Mol Sci 2023; 24(5): 5045.
[http://dx.doi.org/10.3390/ijms24055045] [PMID: 36902485]
[4]
Fišere I, Groma V, Svirskis Š, Strautmane E, Gardovskis A. Evaluation of clinical manifestations of hemorrhoidal disease, carried out surgeries and prolapsed anorectal tissues: Associations with ABO blood groups of patients. J Clin Med 2023; 12(15): 5119.
[http://dx.doi.org/10.3390/jcm12155119] [PMID: 37568521]
[5]
Abegaz SB. Human ABO blood groups and their associations with different diseases. BioMed Res Int 2021; 2021: 1-9.
[http://dx.doi.org/10.1155/2021/6629060] [PMID: 33564677]
[6]
Ghamdi FA, Naqvi S, Alabassi FA, et al. Alterations in clinical characteristics of blood donors post COVID-19 recovery. Curr Pharm Des 2022; 28(12): 981-92.
[http://dx.doi.org/10.2174/1381612828666220322123225] [PMID: 35319357]
[7]
Qin L, Gao D, Wang Q, et al. ABO blood group and the risk and prognosis of lymphoma. J Inflamm Res 2023; 16: 769-78.
[http://dx.doi.org/10.2147/JIR.S401818] [PMID: 36855543]
[8]
Cui H, Qu Y, Zhang L, et al. Epidemiological and genetic evidence for the relationship between ABO blood group and human cancer. Int J Cancer 2023; 153(2): 320-30.
[http://dx.doi.org/10.1002/ijc.34533] [PMID: 37074298]
[9]
Liu Y, Chen S, Shen W, Qu X, Li S, Shi Y. Construction and validation of a gastric cancer diagnostic model based on blood groups and tumor markers. J Cancer 2024; 15(3): 729-36.
[http://dx.doi.org/10.7150/jca.88190] [PMID: 38213731]
[10]
Kim J, Yuan C, Amundadottir LT, et al. Relationship between ABO blood group alleles and pancreatic cancer is modulated by secretor (FUT2) genotype, but not Lewis antigen (FUT3) genotype. Cancer Epidemiol Biomarkers Prev 2023; 32(9): 1242-8.
[http://dx.doi.org/10.1158/1055-9965.EPI-23-0009] [PMID: 37342060]
[11]
Liao Y, Liang T, He Y, et al. Correlation between ABO blood group and prognosis of hepatectomy for hepatitis B virus-associated hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2023; 35(9): 1012-22.
[http://dx.doi.org/10.1097/MEG.0000000000002593] [PMID: 37505977]
[12]
Lilova Z, Hassan F, Riaz M, et al. Blood group and ischemic stroke, myocardial infarction, and peripheral vascular disease: A meta-analysis of over 145,000 cases and 2,000,000 controls. J Stroke Cerebrovasc Dis 2023; 32(8): 107215.
[http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2023.107215] [PMID: 37336185]
[13]
Jajosky RP, Wu SC, Zheng L, et al. ABO blood group antigens and differential glycan expression: Perspective on the evolution of common human enzyme deficiencies. iScience 2023; 26(1): 105798.
[http://dx.doi.org/10.1016/j.isci.2022.105798] [PMID: 36691627]
[14]
Jung JY, Oh JH, Lee DH, Lee S, Chung JH. Blood Type B antigen modulates cell migration through regulating cdc42 expression and activity in HaCaT cells. J Cell Physiol 2013; 228(11): 2243-51.
[http://dx.doi.org/10.1002/jcp.24393] [PMID: 23625752]
[15]
Guo X, Gu L, Li Y, et al. Histological and molecular glioblastoma, IDH-wildtype: A real-world landscape using the 2021 WHO classification of central nervous system tumors. Front Oncol 2023; 13: 1200815.
[http://dx.doi.org/10.3389/fonc.2023.1200815] [PMID: 37483487]
[16]
Park YW, Vollmuth P, Foltyn‐Dumitru M, et al. The 2021 WHO classification for gliomas and implications on imaging diagnosis: Part 1-key points of the fifth edition and summary of imaging findings on adult-type diffuse gliomas. J Magn Reson Imaging 2023; 58(3): 677-89.
[17]
Toader C, Eva L, Costea D, et al. Low-grade gliomas: Histological subtypes, molecular mechanisms, and treatment strategies. Brain Sci 2023; 13(12): 1700.
[http://dx.doi.org/10.3390/brainsci13121700] [PMID: 38137148]
[18]
van den Bent MJ, Geurts M, French PJ, et al. Primary brain tumours in adults. Lancet 2023; 402(10412): 1564-79.
[http://dx.doi.org/10.1016/S0140-6736(23)01054-1] [PMID: 37738997]
[19]
Reuss DE. Updates on the WHO diagnosis of IDH-mutant glioma. J Neurooncol 2023; 162(3): 461-9.
[http://dx.doi.org/10.1007/s11060-023-04250-5] [PMID: 36717507]
[20]
Aldecoa I. Practice guidelines for the diagnosis of glioblastoma. In: New Insights Into Glioblastoma. Elsevier 2023; pp. 11-32.
[http://dx.doi.org/10.1016/B978-0-323-99873-4.00011-6]
[21]
Alimohamadi M, Larijani A, Pour-Rashidi A, et al. Comparative analysis of the prognostic significance of IDH, TERT, EGFR and MGMT status in patients with adult Non-H3-altered grade 4 Gliomas: A prospective cohort study. World Neurosurg 2023; 181: e628-39.
[PMID: 37914076]
[22]
Wu Y, Wang X, Zhang M, Wu D. Molecular biomarkers and recent liquid biopsy testing progress: A review of the application of biosensors for the diagnosis of gliomas. Molecules 2023; 28(15): 5660.
[http://dx.doi.org/10.3390/molecules28155660] [PMID: 37570630]
[23]
Orzan F, De Bacco F, Lazzarini E, et al. Liquid biopsy of cerebrospinal fluid enables selective profiling of glioma molecular subtypes at first clinical presentation. Clin Cancer Res 2023; 29(7): 1252-66.
[http://dx.doi.org/10.1158/1078-0432.CCR-22-2903] [PMID: 36648487]
[24]
Pilotto Heming C, Niemeyer Filho P, Moura-Neto V, Aran V. Recent advances in the use of liquid biopsy to fight central nervous system tumors. Cancer Treat Res Commun 2023; 35: 100709.
[http://dx.doi.org/10.1016/j.ctarc.2023.100709] [PMID: 37088042]
[25]
Fang S, Li L, Weng S, et al. Altering patterns of sensorimotor network in patients with different pathological diagnoses and glioma‐related epilepsy under the latest glioma classification of the central nervous system. CNS Neurosci Ther 2023; 29(5): 1368-78.
[http://dx.doi.org/10.1111/cns.14109] [PMID: 36740245]
[26]
Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: Comparison of immunohistochemistry and sequencing. Brain Tumor Pathol 2011; 28(2): 115-23.
[http://dx.doi.org/10.1007/s10014-011-0023-7] [PMID: 21344322]
[27]
Al-Sawat A, Alswat S, Alosaimi R, et al. Relationship between ABO Blood group and the risk of colorectal cancer: A retrospective multicenter study. J Clin Med Res 2022; 14(3): 119-25.
[http://dx.doi.org/10.14740/jocmr4691] [PMID: 35464604]
[28]
Wang C, Zhou J, Wang L, et al. ABO blood groups and expression of blood group antigens of epithelial ovarian cancer in Chinese women. Cancer Med 2023; 12(6): 7498-507.
[http://dx.doi.org/10.1002/cam4.5476] [PMID: 36415180]
[29]
Allouh MZ, Al Barbarawi MM, Hiasat MY, Al-Qaralleh MA, Ababneh EI. Glioblastoma and ABO blood groups: Further evidence of an association between the distribution of blood group antigens and brain tumours. Blood Transfus 2017; 15(6): 543-7.
[PMID: 27416574]
[30]
Turowski K, Czochra M. ABO blood groups in glioblastoma multiforme. Neurol Neurochir Pol 1979; 13(2): 173-6.
[PMID: 221850]
[31]
Akca Z, Mutlu H, Erden A, Büyükcelik A, Sezer E, Inal A. The relationship between ABO blood group and glioblastoma multiforme. Med Sci 2014; 3(4): 1639-47.
[http://dx.doi.org/10.5455/medscience.2014.03.8160]
[32]
Patidar GK, Dhiman Y, Hazarika A. Association of ABO blood group antigen and neurological tumors. J Neuroanaesthesiol Crit Care 2022; 9(02): 093-8.
[33]
Azachi WB, Dakop KM. Blood Groups: More than Inheritance of Antigenic Substances : Susceptibility to Some Diseases. IntechOpen 2022.
[http://dx.doi.org/10.5772/intechopen.94700]
[34]
Singh S, Deora H, Neyaz A, et al. Trends in clinico-epidemiology profile of surgically operated glioma patients in a tertiary care center over 12 years—through the looking glass! Egypt J Neurosurg 2021; 36(1): 32.
[http://dx.doi.org/10.1186/s41984-021-00118-w]
[35]
Gates EDH, Weinberg JS, Prabhu SS, et al. Estimating local cellular density in glioma using MR imaging data. AJNR Am J Neuroradiol 2021; 42(1): 102-8.
[http://dx.doi.org/10.3174/ajnr.A6884] [PMID: 33243897]
[36]
Girardi F, Matz M, Stiller C, et al. Global survival trends for brain tumors, by histology: Analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000–2014 (CONCORD-3). Neuro-oncol 2023; 25(3): 580-92.
[http://dx.doi.org/10.1093/neuonc/noac217] [PMID: 36355361]
[37]
Paul P, Banerjee M. A comprehensive view (COUP D’OEIL) of brain tumors from eastern India. World Neurosurg 2023; 175: e1237-45.
[http://dx.doi.org/10.1016/j.wneu.2023.04.104] [PMID: 37427703]
[38]
Jarmuzek P, Kozlowska K, Defort P, Kot M, Zembron-Lacny A. Prognostic values of systemic inflammatory immunological markers in glioblastoma: A systematic review and meta-analysis. Cancers 2023; 15(13): 3339.
[http://dx.doi.org/10.3390/cancers15133339] [PMID: 37444448]
[39]
Elguindy M, Young JS, Mondal I, Lu RO, Ho WS. Glioma–immune cell crosstalk in tumor progression. Cancers 2024; 16(2): 308.
[http://dx.doi.org/10.3390/cancers16020308] [PMID: 38254796]
[40]
Frontiñán-Rubio J, Llanos-González E, García-Carpintero S, et al. CoQ10 reduces glioblastoma growth and infiltration through proteome remodeling and inhibition of angiogenesis and inflammation. Cell Oncol 2023; 46(1): 65-77.
[http://dx.doi.org/10.1007/s13402-022-00734-0] [PMID: 36319818]
[41]
Caverzán MD, Beaugé L, Oliveda PM, Cesca González B, Bühler EM, Ibarra LE. Exploring monocytes-macrophages in immune microenvironment of glioblastoma for the design of novel therapeutic strategies. Brain Sci 2023; 13(4): 542.
[http://dx.doi.org/10.3390/brainsci13040542] [PMID: 37190507]
[42]
Maas RR, Soukup K, Fournier N, et al. The local microenvironment drives activation of neutrophils in human brain tumors. Cell 2023; 186(21): 4546-66.
[http://dx.doi.org/10.1016/j.cell.2023.08.043]
[43]
Rugambwa TK, Abdihamid O, Zhang X, et al. Neutrophil–lymphocyte ratio and platelet–lymphocyte ratio as potential predictive markers of treatment response in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Front Oncol 2023; 13: 1181248.
[http://dx.doi.org/10.3389/fonc.2023.1181248] [PMID: 38023176]
[44]
Förnvik K, Maddahi A, Liljedahl E, Osther K, Salford LG, Redebrandt HN. What is the role of CRP in glioblastoma? Cancer Treat Res Commun 2021; 26: 100293.
[http://dx.doi.org/10.1016/j.ctarc.2020.100293] [PMID: 33385735]
[45]
Carrano A, Juarez JJ, Incontri D, Ibarra A, Guerrero Cazares H. Sex-specific differences in glioblastoma. Cells 2021; 10(7): 1783.
[http://dx.doi.org/10.3390/cells10071783] [PMID: 34359952]
[46]
Rosales C. Neutrophils at the crossroads of innate and adaptive immunity. J Leukoc Biol 2020; 108(1): 377-96.
[http://dx.doi.org/10.1002/JLB.4MIR0220-574RR] [PMID: 32202340]
[47]
Friedmann-Morvinski D, Hambardzumyan D. Monocyte-neutrophil entanglement in glioblastoma. J Clin Invest 2023; 133(1): e163451.
[http://dx.doi.org/10.1172/JCI163451] [PMID: 36594465]
[48]
Cooper J, Pastorello Y, Slevin M. A meta-analysis investigating the relationship between inflammation in autoimmune disease, elevated CRP, and the risk of dementia. Front Immunol 2023; 14: 1087571.
[http://dx.doi.org/10.3389/fimmu.2023.1087571] [PMID: 36776896]
[49]
Auezova R, Ivanova N, Akshulakov S, et al. Isocitrate dehydrogenase 1 mutation is associated with reduced levels of inflammation in glioma patients. Cancer Manag Res 2019; 11: 3227-36.
[http://dx.doi.org/10.2147/CMAR.S195754] [PMID: 31114362]
[50]
Wach J, Apallas S, Schneider M, et al. Baseline serum C-reactive protein and plasma fibrinogen-based score in the prediction of survival in glioblastoma. Front Oncol 2021; 11: 653614.
[http://dx.doi.org/10.3389/fonc.2021.653614] [PMID: 33747971]
[51]
Hotta T, Nakashima K, Hata K, Tsubata Y, Isobe T. High serum C-reactive protein levels predict survival in patients with treated advanced lung adenocarcinoma. J Thorac Dis 2021; 13(3): 1476-84.
[http://dx.doi.org/10.21037/jtd-20-3123] [PMID: 33841940]
[52]
Muddobalaiah P, Ravi V, Thammanna CC, Sagar BKC, Swamy NSR. Acid and alkaline phosphatases specific activities and expression as biomarkers in brain tumor grading and correlation of anaplastic oligodendroglioma G-III to meningiomas G-I among brain tumors and their primary culture. J Chem Neuroanat 2022; 125: 102140.
[http://dx.doi.org/10.1016/j.jchemneu.2022.102140] [PMID: 35914649]
[53]
Chen SL, Li JP, Li LF, Zeng T, He X. Elevated preoperative serum alanine aminotransferase/aspartate aminotransferase (ALT/AST) ratio is associated with better prognosis in patients undergoing curative treatment for gastric adenocarcinoma. Int J Mol Sci 2016; 17(6): 911.
[http://dx.doi.org/10.3390/ijms17060911] [PMID: 27294917]
[54]
Chiocca EA, Yu JS, Lukas RV, et al. Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial. Sci Transl Med 2019; 11(505): eaaw5680.
[http://dx.doi.org/10.1126/scitranslmed.aaw5680] [PMID: 31413142]
[55]
Claps G, Faouzi S, Quidville V, et al. The multiple roles of LDH in cancer. Nat Rev Clin Oncol 2022; 19(12): 749-62.
[http://dx.doi.org/10.1038/s41571-022-00686-2] [PMID: 36207413]
[56]
McGovern J, Dolan RD, Simmons CPL, et al. Lactate dehydrogenase: Relationship with the diagnostic GLIM criterion for cachexia in patients with advanced cancer. Br J Cancer 2023; 128(5): 760-5.
[http://dx.doi.org/10.1038/s41416-022-02099-5] [PMID: 36517550]
[57]
Chen XY, Chen JY, Chen Y, et al. Preoperative serum lactate dehydrogenase level predicts progression and prognosis in patients with glioma. Clin Neurol Neurosurg 2021; 209: 106912.
[http://dx.doi.org/10.1016/j.clineuro.2021.106912] [PMID: 34509141]
[58]
Pei YY, Zhang Y, Liu ZR, et al. Lactate dehydrogenase as promising marker for prognosis of brain metastasis. J Neurooncol 2022; 159(2): 359-68.
[http://dx.doi.org/10.1007/s11060-022-04070-z] [PMID: 35794505]

Rights & Permissions Print Cite
© 2025 Bentham Science Publishers | Privacy Policy